When Will the Next Pandemic Occur?

Total Page:16

File Type:pdf, Size:1020Kb

When Will the Next Pandemic Occur? WHEN WILL THE NEXT Any Time. PANDEMIC Infectious disease outbreaks now occur 3 times more often OCCUR? than 40 years ago. WHAT IS MOST LIKELY TO CAUSE THE NEXT PANDEMIC THREAT? We don’t know. But, of about 2 dozen viral families capable of infecting humans, 6 families (Adenoviridae, Coronaviridae, Orthomyxoviridae, Paramyxoviridae, Picornaviridae, and Poxviridae) have these traits that will likely cause the next pandemic. No immunity – No preexisting immunity in the world’s population Airborne – Spread via respiratory transmission Silent – Transmissible by infected people who have no symptoms Harmful – No existing, effective therapeutics or vaccines ARE WE PREPARED TO MAKE VACCINES, ANTIVIRALS, AND TESTS EVEN FASTER DURING THE NEXT PANDEMIC? No. Currently there is $0 sustained federal funding dedicated to developing medical countermeasures for unknown viral threats. Developing the COVID-19 vaccines in 1 year was only possible because of 15 years of YEARS $ BILLION 15 + 12 prior coronavirus research + a $12 billion federal investment. HOW CAN WE MAKE MEDICAL COUNTERMEASURES WITHOUT KNOWING WHICH DISEASE (“DISEASE X”) WILL STRIKE NEXT? By focusing medical countermeasure development efforts on the viral families most likely to cause pandemics, rather than on a specific virus that may or may not present a future threat. The United States should fund a new dedicated DISEASE Disease X Medical Countermeasure Program that leverages technologies and vaccine platforms most suitable to the viral families that are likely to cause future catastrophic disease outbreaks. Medical countermeasures against 1 member of a viral family could easily be adapted to another member quickly when the next threat emerges. With this flexible approach, private–public partnerships could develop vaccines, antivirals, and tests for a range of unknown potential pandemic pathogens in months, not years. Stopping the next COVID-19-type pandemic a MONTH $ BILLION month earlier in the United States would save 1 EARLIER = 500 SAVED approximately $500 billion. Center for Health Security centerforhealthsecurity.org/disease-x.
Recommended publications
  • Exploring Mental Health & COVID-19: How a Pandemic Could Become
    Eastern Kentucky University Encompass Honors Theses Student Scholarship Spring 5-2021 Exploring Mental Health & COVID-19: How a Pandemic Could Become America's Next Mental Health Crisis Ashley D. Shofner Eastern Kentucky University, [email protected] Follow this and additional works at: https://encompass.eku.edu/honors_theses Recommended Citation Shofner, Ashley D., "Exploring Mental Health & COVID-19: How a Pandemic Could Become America's Next Mental Health Crisis" (2021). Honors Theses. 834. https://encompass.eku.edu/honors_theses/834 This Open Access Thesis is brought to you for free and open access by the Student Scholarship at Encompass. It has been accepted for inclusion in Honors Theses by an authorized administrator of Encompass. For more information, please contact [email protected]. EASTERN KENTUCKY UNIVERSITY Exploring Mental Health and COVID-19: How a Pandemic Could Become America’s Next Mental Health Crisis Honors Thesis Submitted in Partial Fulfillment of the Requirements of HON 420 Spring 2021 By Ashley D. Shofner Mentor Dr. Molly A. McKinney Associate Professor, Department of Health Promotion and Administration 3 An Abstract Of Exploring Mental Health and COVID-19: How a Pandemic Could Become America’s Next Mental Health Crisis By Ashley D. Shofner Mentor Dr. Molly A. McKinney Associate Professor, Department of Health Promotion and Administration Abstract Description: A pandemic can be described as an epidemic disease that has spread over a large geographical area and has become prevalent in numerous sectors of the globe. In 2020, just over 100 years since our last major pandemic, the 1918 Influenza outbreak, the global community is facing yet another threat: COVID-19.
    [Show full text]
  • Guide for Common Viral Diseases of Animals in Louisiana
    Sampling and Testing Guide for Common Viral Diseases of Animals in Louisiana Please click on the species of interest: Cattle Deer and Small Ruminants The Louisiana Animal Swine Disease Diagnostic Horses Laboratory Dogs A service unit of the LSU School of Veterinary Medicine Adapted from Murphy, F.A., et al, Veterinary Virology, 3rd ed. Cats Academic Press, 1999. Compiled by Rob Poston Multi-species: Rabiesvirus DCN LADDL Guide for Common Viral Diseases v. B2 1 Cattle Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 2 Deer and Small Ruminants Please click on the principle system involvement Generalized viral disease Respiratory viral disease Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 3 Swine Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 4 Horses Please click on the principle system involvement Generalized viral diseases Neurological viral diseases Respiratory viral diseases Enteric viral diseases Abortifacient/neonatal viral diseases Viral infections affecting the skin Back to the Beginning DCN LADDL Guide for Common Viral Diseases v. B2 5 Dogs Please click on the principle system involvement Generalized viral diseases Respiratory viral diseases Enteric viral diseases Reproductive/neonatal viral diseases Back to the Beginning DCN LADDL Guide for Common Viral Diseases v.
    [Show full text]
  • Key Factors That Enable the Pandemic Potential of RNA Viruses and Inter-Species Transmission: a Systematic Review
    viruses Review Key Factors That Enable the Pandemic Potential of RNA Viruses and Inter-Species Transmission: A Systematic Review Santiago Alvarez-Munoz , Nicolas Upegui-Porras , Arlen P. Gomez and Gloria Ramirez-Nieto * Microbiology and Epidemiology Research Group, Facultad de Medicina Veterinaria y de Zootecnia, Universidad Nacional de Colombia, Bogotá 111321, Colombia; [email protected] (S.A.-M.); [email protected] (N.U.-P.); [email protected] (A.P.G.) * Correspondence: [email protected]; Tel.: +57-1-3-16-56-93 Abstract: Viruses play a primary role as etiological agents of pandemics worldwide. Although there has been progress in identifying the molecular features of both viruses and hosts, the extent of the impact these and other factors have that contribute to interspecies transmission and their relationship with the emergence of diseases are poorly understood. The objective of this review was to analyze the factors related to the characteristics inherent to RNA viruses accountable for pandemics in the last 20 years which facilitate infection, promote interspecies jump, and assist in the generation of zoonotic infections with pandemic potential. The search resulted in 48 research articles that met the inclusion criteria. Changes adopted by RNA viruses are influenced by environmental and host-related factors, which define their ability to adapt. Population density, host distribution, migration patterns, and the loss of natural habitats, among others, have been associated as factors in the virus–host interaction. This review also included a critical analysis of the Latin American context, considering its diverse and unique social, cultural, and biodiversity characteristics. The scarcity of scientific information is Citation: Alvarez-Munoz, S.; striking, thus, a call to local institutions and governments to invest more resources and efforts to the Upegui-Porras, N.; Gomez, A.P.; study of these factors in the region is key.
    [Show full text]
  • Survival of Human Norovirus Surrogates in Juices and Their Inactivation Using Novel Methods
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Masters Theses Graduate School 5-2011 Survival of Human Norovirus Surrogates In Juices and their Inactivation Using Novel Methods Katie Marie Horm [email protected] Follow this and additional works at: https://trace.tennessee.edu/utk_gradthes Recommended Citation Horm, Katie Marie, "Survival of Human Norovirus Surrogates In Juices and their Inactivation Using Novel Methods. " Master's Thesis, University of Tennessee, 2011. https://trace.tennessee.edu/utk_gradthes/882 This Thesis is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Masters Theses by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a thesis written by Katie Marie Horm entitled "Survival of Human Norovirus Surrogates In Juices and their Inactivation Using Novel Methods." I have examined the final electronic copy of this thesis for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Master of Science, with a major in Food Science and Technology. Doris H. D'Souza, Major Professor We have read this thesis and recommend its acceptance: Federico M. Harte, Gina M. Pighetti Accepted for the Council: Carolyn R. Hodges Vice Provost and Dean of the Graduate School (Original signatures are on file with official studentecor r ds.) Survival of Human Norovirus Surrogates In Juices and their Inactivation Using Novel Methods A Thesis Presented for the Master of Science Degree The University of Tennessee, Knoxville Katie Marie Horm May 2011 Acknowledgments I would like to think my major professor/advisor Dr.
    [Show full text]
  • CEPI and COVID-19 VACCINES
    CEPI and COVID-19 VACCINES June 9, 2020 Nicole Lurie, MD, MSPH Strategic Advisor to the CEO and Incident Manager, COVID response team CEPI A world in which epidemics are no longer a threat to humanity CEPI accelerates development of vaccines against emerging infectious diseases and enables equitable access to these vaccines for affected populations during outbreaks 2 Image left slide (right-click to replace image) CEPI Strategic Objectives Preparedness Response Sustainability Advance access to safe and Accelerate the research, Create durable and equitable effective vaccines against development and use of solutions for outbreak emerging infectious diseases vaccines during outbreaks response capacity 3 3 Column slide Small images or graphics can be used to highlight key items. These should always be circular CEPI has multiple investments against its priority pathogens MERS Lassa Nipah Chikungunya Rift Valley fever Disease X 5 vaccine 6 vaccine 4 vaccine 2 vaccine 2 vaccine 3 platform candidates candidates candidates candidates candidates technologies 4 COVID-19 portfolio goals Speed Scale Access Developing Covid-19 vaccines at Scaling up and scaling out vaccine Working with global partners to pandemic speed manufacturing capacity ensure fair allocation of COVID-19 vaccines 5 CEPI vaccine development so far…. 23th May 31st Dec 2019 11th March 12th April 14th Feb First meeting of the ACT WHO notified of pneumonia-like case Wellcome Trust launch First cases reported in WHO declares Accelerator cluster in Wuhan, China COVID-Zero resource Africa
    [Show full text]
  • Genetic Content and Evolution of Adenoviruses Andrew J
    Journal of General Virology (2003), 84, 2895–2908 DOI 10.1099/vir.0.19497-0 Review Genetic content and evolution of adenoviruses Andrew J. Davison,1 Ma´ria Benko´´ 2 and Bala´zs Harrach2 Correspondence 1MRC Virology Unit, Institute of Virology, Church Street, Glasgow G11 5JR, UK Andrew Davison 2Veterinary Medical Research Institute, Hungarian Academy of Sciences, H-1581 Budapest, [email protected] Hungary This review provides an update of the genetic content, phylogeny and evolution of the family Adenoviridae. An appraisal of the condition of adenovirus genomics highlights the need to ensure that public sequence information is interpreted accurately. To this end, all complete genome sequences available have been reannotated. Adenoviruses fall into four recognized genera, plus possibly a fifth, which have apparently evolved with their vertebrate hosts, but have also engaged in a number of interspecies transmission events. Genes inherited by all modern adenoviruses from their common ancestor are located centrally in the genome and are involved in replication and packaging of viral DNA and formation and structure of the virion. Additional niche-specific genes have accumulated in each lineage, mostly near the genome termini. Capture and duplication of genes in the setting of a ‘leader–exon structure’, which results from widespread use of splicing, appear to have been central to adenovirus evolution. The antiquity of the pre-vertebrate lineages that ultimately gave rise to the Adenoviridae is illustrated by morphological similarities between adenoviruses and bacteriophages, and by use of a protein-primed DNA replication strategy by adenoviruses, certain bacteria and bacteriophages, and linear plasmids of fungi and plants.
    [Show full text]
  • First Description of Adenovirus, Enterovirus, Rotavirus and Torque
    First description of Adenovirus, Enterovirus, Rotavirus and Torque teno virus in water samples collected from the Arroio Dilúvio, Porto Alegre, Brazil Vecchia, AD.a,b, Fleck, JD.a,b, Comerlato, J.c, Kluge, M.b, Bergamaschi, B.c, Da Silva, JVS.b, Da Luz, RB.b, Teixeira, TF.b, Garbinatto, GN.d, Oliveira, DV.d, Zanin, JG.d, Van der Sand, S.d, Frazzon, APG.d, Franco, AC.c, Roehe, PM.c,e and Spilki, FR.a,b* aPrograma de Pós-Graduação em Qualidade Ambiental, Universidade Feevale, CEP 93352-000, Novo Hamburgo, RS, Brazil bLaboratório de Microbiologia Molecular, Instituto de Ciências da Saúde, Universidade Feevale, CEP 93352-000, Novo Hamburgo, RS, Brazil cLaboratório de Virologia, Departamento de Microbiologia, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul – UFRGS, Av. Sarmento Leite, 500, CEP 90050-170, Porto Alegre, RS, Brazil dDepartamento de Microbiologia, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul – UFRGS, Av. Sarmento Leite, 500, CEP 90050-170, Porto Alegre, RS, Brazil eInstituto de Pesquisa Veterinária “Desidério Finamor” – IPVDF, Fundação Estadual de Pesquisa Agropecuária – FEPAGRO-Saúde Animal, Estrada do Conde, 6000, CEP 92990-000, Eldorado do Sul, RS, Brazil *e-mail: [email protected] Received May 11, 2011 – Accepted July 14, 2011 – Distributed May 31, 2012 (With 1 figure) Abstract Adenovirus (AdV), enterovirus (EV), genogroup A rotaviruses (GARV) and Torque teno virus (TTV) are non-enveloped viral agents excreted in feces and so may contaminate water bodies. In the present study, the molecular detection of these viruses was performed in samples of surface water collected from the Arroio Dilúvio, a waterstream that crosses the city of Porto Alegre, RS, Brazil, receiving great volumes of non-treated sewage from a large urban area.
    [Show full text]
  • COVID-19 (Novel Coronavirus): What We Know, What We Don’T Know, and How We Can Plan Within Our Communities
    COVID-19 (novel coronavirus): What we know, what we don’t know, and how we can plan within our communities March 5, 2020 Andrew Lover, MS MPH PhD Dept. of Biostatistics and Epidemiology [email protected] School of Public Health and Health Sciences Updated Mar 7; v1.1. Overview 1. Some background 2. The virus and epidemiology 3. Response measures and community preparedness 4. Q & A School of Public Health and Health Sciences 2 Disclaimers All opinions in this talk are my personal views, and do not represent those of the Department of Biostatistics and Epidemiology; the School of Public Health and Health Sciences; or UMass-Amherst. Guidance is being rapidly updated; always consult your local, state and federal authorities for the most up-to-date information. (mass.gov and cdc.gov) General note: most/many current studies are preprints and are not yet peer reviewed; and data change hourly/daily. School of Public Health and Health Sciences 3 Terminology § Coronaviruses are a small class of human pathogens; four of which cause ‘normal’ respiratory infections. § Two others may cause severe infections: SARS-CoV, and MERS-CoV. MERS-CoV § Original name (Jan 2020): Wuhan flu or novel coronavirus-2019 § Current standard (allows for expansion) § Illness: COVID-19 (“coronavirus disease”) § Virus: SARS-CoV-2 § This structure parallels HIV/AIDS School of Public Health and Health Sciences 4 Population-level metrics § Endemic: The constant presence of a disease or infectious agent within a given geographic area or population group § Epidemic: The occurrence in a community or region of cases of an illness clearly in “excess of normal expectancy” (preferred) § Outbreak: An epidemic limited to localized increase in the incidence of a disease (avoid) § Pandemic: An epidemic occurring over a very wide area, crossing international boundaries and usually affecting a large number of people (national or global), but no specific criteria School of Public Health and Health Sciences 5 The first signal….
    [Show full text]
  • On the Coronaviruses and Their Associations with the Aquatic Environment and Wastewater
    water Review On the Coronaviruses and Their Associations with the Aquatic Environment and Wastewater Adrian Wartecki 1 and Piotr Rzymski 2,* 1 Faculty of Medicine, Poznan University of Medical Sciences, 60-812 Pozna´n,Poland; [email protected] 2 Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Pozna´n,Poland * Correspondence: [email protected] Received: 24 April 2020; Accepted: 2 June 2020; Published: 4 June 2020 Abstract: The outbreak of Coronavirus Disease 2019 (COVID-19), a severe respiratory disease caused by betacoronavirus SARS-CoV-2, in 2019 that further developed into a pandemic has received an unprecedented response from the scientific community and sparked a general research interest into the biology and ecology of Coronaviridae, a family of positive-sense single-stranded RNA viruses. Aquatic environments, lakes, rivers and ponds, are important habitats for bats and birds, which are hosts for various coronavirus species and strains and which shed viral particles in their feces. It is therefore of high interest to fully explore the role that aquatic environments may play in coronavirus spread, including cross-species transmissions. Besides the respiratory tract, coronaviruses pathogenic to humans can also infect the digestive system and be subsequently defecated. Considering this, it is pivotal to understand whether wastewater can play a role in their dissemination, particularly in areas with poor sanitation. This review provides an overview of the taxonomy, molecular biology, natural reservoirs and pathogenicity of coronaviruses; outlines their potential to survive in aquatic environments and wastewater; and demonstrates their association with aquatic biota, mainly waterfowl. It also calls for further, interdisciplinary research in the field of aquatic virology to explore the potential hotspots of coronaviruses in the aquatic environment and the routes through which they may enter it.
    [Show full text]
  • Adenovirus-Host Interactions: Implications for Tropism and Therapy
    Adenovirus-host interactions: implications for tropism and therapy Annasara Lenman Department of Clinical Microbiology Umeå 2016 Responsible publisher under Swedish law: the Dean of the Medical Faculty This work is protected by the Swedish Copyright Legislation (Act 1960:729) ISBN: 978-91-7601-453-0 ISSN: 0346-6612-1798 Omslag gjort m.h.a. familj & vänner. Grafisk design av Lina Cabal ([email protected]). Elektronisk version tillgänglig på http://umu.diva-portal.org/ Tryck/Printed by: Print & Media Umeå, Sverige 2016 Till min älskade familj och mina underbara vänner Table of Contents TABLE OF CONTENTS .................................................................................. I ABSTRACT ................................................................................................... III SUMMARY IN SWEDISH-POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ SVENSKA ............................................................ VI ABBREVIATIONS ....................................................................................... VIII LIST OF PAPERS .......................................................................................... X INTRODUCTION ............................................................................................ 1 HISTORY ....................................................................................................... 1 TAXONOMY ................................................................................................... 2 CLINICAL AND PATHOLOGICAL ASPECTS .........................................................
    [Show full text]
  • Chronic Viral Infections Vs. Our Immune System: Revisiting Our View of Viruses As Pathogens
    Chronic Viral Infections vs. Our Immune System: Revisiting our view of viruses as pathogens Tiffany A. Reese Assistant Professor Departments of Immunology and Microbiology Challenge your idea of classic viral infection and disease • Define the microbiome and the virome • Brief background on persistent viruses • Illustrate how viruses change disease susceptibility – mutualistic symbiosis – gene + virus = disease phenotype – virome in immune responses Bacteria-centric view of the microbiome The microbiome defined Definition of microbiome – Merriam-Webster 1 :a community of microorganisms (such as bacteria, fungi, and viruses) that inhabit a particular environment and especially the collection of microorganisms living in or on the human body 2 :the collective genomes of microorganisms inhabiting a particular environment and especially the human body Virome Ø Viral component of the microbiome Ø Includes both commensal and pathogenic viruses Ø Viruses that infect host cells Ø Virus-derived elements in host chromosomes Ø Viruses that infect other organisms in the body e.g. phage/bacteria Viruses are everywhere! • “intracellular parasites with nucleic acids that are capable of directing their own replication and are not cells” – Roossinck, Nature Reviews Microbiology 2011. • Viruses infect all living things. • We are constantly eating and breathing viruses from our environment • Only a small subset of viruses cause disease. • We even carry viral genomes as part of our own genetic material! Diverse viruses all over the body Adenoviridae Picornaviridae
    [Show full text]
  • An Overview of COVID-19 Vaccine Efficacy Trials
    An Overview of COVID-19 Vaccine Efficacy Trials NISS-Merck Meet Up January 13, 2021 \ Natalie Dean Department of Biostatistics PHHP/COM Emerging Pathogens Institute University of Florida [email protected] VACCINE BASICS COVID- 19 VACCINES WHO R&D Blueprint Prioritized pathogens Crimean Congo Hemorrhagic Fever (CCHF) Ebola and Marburg virus disease Lassa fever MERS-CoV and SARS Nipah and henipaviral diseases Rift Valley Fever (RVF) Zika Disease X COVID- 19 VACCINES Expectations for COVID-19 vaccines “The principal goal of a vaccine efficacy trial is to obtain efficacy and effectiveness data that can support broader use of a vaccine under a defined regulatory framework.” Intended use for COVID-19: billions vaccinated Dean et al. 2019 https://stm.sciencemag.org/content/11/499/eaat0360.abstract COVID- 19 VACCINES Regulatory pathway for vaccines Preclinical data REGULATORY Phase 1 trials Evidence of safety APPROVAL and anti-disease Phase 2 trials activity in animals Smallest trials Phase 3 trials Requires a First-in-human Larger trials validated animal Focus on safety model More safety data Largest trials Establish dosing More immune Field trials Some immune response data response data Disease-related Explore sub- primary outcome groups (e.g. prevent COVID-19) More safety data COVID- 19 VACCINES Accelerating this pathway during a pandemic Accelerated review process Emergency Use Authorization instead of full licensure Preclinical data REGULATORY Phase 1 trials Evidence of safety APPROVAL and anti-disease Phase 2 trials activity in animals Smallest trials Phase 3 trials Requires a First-in-human Larger trials validated animal Focus on safety model More safety data Largest trials Establish dosing More immune Field trials Some immune response data Disease-related response data Explore sub- Start scaling up manufacturing primary outcome before receiving regulatory groups (e.g.
    [Show full text]